GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tafolecimab   Click here for help

GtoPdb Ligand ID: 12517

Synonyms: IBI-306 | IBI306 | Sintbilo®
Approved drug
tafolecimab is an approved drug (China (2023))
Compound class: Antibody
Comment: Tafolecimab (IBI-306; Innovent Biologics) is a fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. Based on protein sequence alignments, we suspect that tafolecimab is one of the monoclonals that are claimed in Innovent Biologics' patent US11485795: Anti-PCSK9 antibody and use thereof [4].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2023)
International Nonproprietary Names Click here for help
INN number INN
11061 tafolecimab
Synonyms Click here for help
IBI-306 | IBI306 | Sintbilo®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 972
Other databases
GtoPdb PubChem SID 479821307
Search PubMed clinical trials tafolecimab
Search PubMed titles tafolecimab
Search PubMed titles/abstracts tafolecimab